ENTITY

Hutchmed China Ltd (13 HK)

190

Analysis

Industrials • Hong Kong

HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.

more

Refresh

Exchange Announcement • 02 Jan 2025 08:00

Voluntary Announcement - Hutchmed Announces Nda Acceptance In China With Priority Review Status For Orpathys And Tagrisso Combination In Lung Cancer Patients With Met Amplification After Progression On First-Line Egfr Inhibitor Therapy

Exchange Announcement • 01 Jan 2025 18:45

Major Transaction In Relation To The Disposal Of 45% Equity Interest In Shanghai Hutchison Pharmaceuticals Limited

Exchange Announcement • 31 Dec 2024 16:33

Appointment Of Cavendish As Joint Corporate Broker In London

Exchange Announcement • 30 Dec 2024 18:28

Blocklisting Six Monthly Return

Exchange Announcement • 13 Dec 2024 08:00

Voluntary Announcement - Hutchmed To Receive Milestone Payment From Takeda Following First European Reimbursement For Fruzaqla (Fruquintinib)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x